Entera Bio Ltd. Form 10-Q Summary
Business Context and Reporting Period
Entera Bio Ltd. is a clinical-stage biotechnology company developing oral peptide and protein replacement therapies using its N-Tab technology. Its lead program, EB613, is an oral PTH(1-34) tablet for osteoporosis; EB612 targets hypoparathyroidism. The company also collaborates with OPKO on oral GLP-2 and oxyntomodulin programs. This unaudited report covers the three months ended March 31, 2024, compared with the same period in 2023.
Financial Performance and Position
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | None | None | No product revenue to date |
| Research and development expense | $735 thousand | $931 thousand | Down 21% |
| General and administrative expense | $1.327 million | $1.294 million | Up 2.6% |
| Operating loss | $2.062 million | $2.212 million | Improved 6.8% |
| Net loss | $2.017 million | $2.190 million | Improved 7.9% |
| Basic and diluted loss per share | $0.05 | $0.08 | Improved |
| Cash used in operating activities | $1.862 million | $1.609 million | Increased $253 thousand |
The filing does not provide a meaningful revenue-based gross or operating margin because the company has not generated product sales. Operating expenses were approximately $2.1 million, with the operating loss equal to total operating expenses. Net financial income was $45 thousand, compared with $22 thousand in Q1 2023.
As of March 31, 2024, cash and cash equivalents were $9.189 million, compared with $11.019 million at December 31, 2023. Cash, cash equivalents and restricted deposits totaled $9.253 million. Total assets were $10.239 million and total liabilities were $1.376 million. The filing reports no material debt; liabilities primarily consisted of accounts payable, accrued expenses and operating lease obligations.
Shareholders’ equity was $8.863 million, down from $10.386 million at year-end 2023, primarily reflecting the quarterly net loss. The company had an accumulated deficit of $106.403 million. Cash flows from investing activities were zero, while financing activities provided $30 thousand from warrant exercises.
Material Changes Versus the Prior Comparable Period
- Research and development expense decreased by $196 thousand, primarily because of lower clinical expenses for the Phase 1 pharmacokinetic study of the new-generation platform and EB612 formulations.
- General and administrative expense increased by $33 thousand. Lower directors’ and officers’ insurance costs were offset by higher compensation, consulting and other fees.
- Net cash used in operating activities increased by $253 thousand, mainly because of an adverse working-capital change, despite the lower operating loss.
- Weighted-average shares outstanding increased to 36.7 million from 28.8 million, contributing to the change in reported loss per share.
- During March 2024, 29,940 warrants were exercised for $30 thousand. In April 2024, the company issued 214,088 shares under its ATM program for net proceeds of $545 thousand and reported an additional 29,940 warrant exercises for $30 thousand.
Guidance, Outlook, Risks and Unusual Items
Management expects existing funds to support operations into the third quarter of 2025 under current plans, including ongoing research and development, completion of the Phase 1 pharmacokinetic study and the OPKO GLP-2/OXM collaboration. Existing resources do not include the funding required for the proposed Phase 3 EB613 osteoporosis study. That study depends on further FDA discussions and additional financing.
The filing states that recurring losses, negative operating cash flows and limited liquidity raise substantial doubt about the company’s ability to continue as a going concern. Management expects to seek additional equity, debt, strategic collaboration or licensing financing, but no committed funding source exists other than the ATM program. Failure to obtain financing could delay, reduce or terminate development activities and could require liquidation.
In March 2024, the company reported positive in vivo pharmacokinetic results from the OPKO GLP-2 collaboration and expects additional in vivo pharmacokinetic and pharmacodynamic data from the GLP-2 and OXM programs during 2024. An investigator-sponsored Phase 2 study of oral PTH tablets for stress fractures in athletes is expected to begin in the second half of 2024.
The company’s research and development and management operations are located in Israel. Management reported no material operational impact or expected program delays from the Israel-Hamas war or the April 2024 conflict involving Iran, but identified escalation, workforce disruption, supply-chain interruption, trade restrictions and financing difficulty as material risks. Other major risks include clinical and regulatory uncertainty, manufacturing and third-party dependence, intellectual-property protection, market acceptance and the need for additional capital.
The company reported approximately $460 thousand of potential pre-interest royalty obligations to the Israeli Innovation Authority and $96 thousand of royalties paid through March 31, 2024. It also had Israeli tax-loss carryforwards of $77.7 million and U.S. subsidiary tax-loss carryforwards of $154 thousand.
Investor Verification Checklist
- Verify the timing, cost and financing plan for the proposed Phase 3 EB613 study.
- Assess whether the projected cash runway into Q3 2025 remains valid after subsequent ATM issuances, warrant exercises and planned development spending.
- Monitor additional equity issuance and potential shareholder dilution under the ATM program and equity compensation grants.
- Review FDA discussions and the status of qualification of total hip bone mineral density as a surrogate endpoint.
- Confirm clinical and preclinical progress for EB613, EB612 and the OPKO GLP-2/OXM programs, including expected 2024 data.
- Evaluate the going-concern uncertainty and the company’s ability to secure financing or strategic partnerships on acceptable terms.
- Monitor the Israel security situation and its potential effects on personnel, research operations, supply chains and capital access.